Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments

NCT00567502 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00567502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00567502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments
Lead sponsor
Shire
Phase
Observational
Overall status
Completed
Start date
May 31, 2005
Completion date
April 30, 2014
Enrollment
3,647 (actual)
Sites
164

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocythemia, essential